Cutting the red tape around biosimilars is one way that the administration can protect U.S. drug innovation and make medicine more affordable for Americans.
Source link
Reducing Pharmaceutical Prices Requires Competition, Not Price-Fixing
Related Posts
School System Slapped With Complaint Over Race Discrimination
Fairfax County Public Schools (FCPS), one of the largest school districts in the…
This state just made ‘misgendering’ grounds for child removal
Just as commonsense, reality-based reforms gain momentum nationwide, Colorado…
Trump pardon czar reflects on journey of hope amid justice system reform
President Donald Trump’s pardon czar Alice Marie Johnson reflected on the…
Diversity is not our strength
That “diversity is our strength” is one of those obvious contradictions that…
Republicans should let the ‘one big, beautiful bill’ die on SALT hill
It won’t carry nearly the same honor as that of my grandfather’s comrades who…
What happens when you tell a philosopher ‘No’
We need more philosophers to resign from their university posts.Graham Parsons,…
The senators to watch in reconciliation’s next battle
Washington breathed a sigh of relief Thursday morning. After weeks of wrangling,…
Fleeing persecution, South African arrivals scramble refugee politics
When dozens of refugees from Africa arrived this week at Dulles International…
Trump has a chance to stop Iran
The fourth round of talks concluded last weekend between the United States and…
Hegseth Launches Task Force To Probe Afghanistan Withdrawal
Defense Secretary Pete Hegseth ordered the creation of a special review panel on…
